Biogen

Banque Pictet & Cie SA cut its position in Biogen Inc. (NASDAQ:BIIB - Free Report) by 15.9% in the first quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 45,434 shares of the biotechnology company's stock after selling 8,562 shares during the period.…

After a full FDA approval last week triggered Medicare coverage of Eisai and Biogen’s Leqembi, doctors are still trying to work out the logistics of testing and reimbursement. | After a full FDA approval last week triggered Medicare coverage of Eisai and Biogen’s Leqembi, doctors are still working out the logistics of testing and reimbursement.…

Five weeks after getting no response from the U.S. | Five weeks after getting no response from the U.S. Department of Health and Human Services on his request for more information on the potential financial impact of Eisai and Biogen’s newly approved Alzheimer’s treatment Leqembi, Sen. Bernie Sanders (I-Vt.) has sent a follow-up letter to…

(Photo Illustration by Pavlo Gonchar/SOPA Images/LightRocket via Getty Images) SOPA Images/LightRocket via Getty Images Key Takeaways Leqembi, the first ever drug for treating the cause of Alzheimers has been approved by the FDA Even so, the makers of the drug Biogen and Eisai have both fallen on the announcement It follows guidance from…

The Levi Strauss & Co. label is seen on jeans in a store at the Woodbury Common Premium Outlets in Central Valley, New York, U.S., February 15, 2022.  Andrew Kelly | Reuters Check out the companies making the biggest moves before the bell: Levi Strauss — The apparel retailer fell 7.7% after…

TOKYO/NEW YORK -- The U.S. Food and Drug Administration on Thursday officially approved lecanemab, an Alzheimer's disease treatment developed by Japanese drugmaker Eisai and American partner Biogen. Lecanemab, marketed as Leqembi, is the first treatment proven to slow the progression of Alzheimer's. The drug is expected to be covered by public medical insurance, paving the…

It’s official: Roughly half a year after the FDA granted an accelerated nod to Eisai and Biogen’s new Alzheimer’s disease med lecanemab, the companies have converted that green light into a full-fl | With a full approval in hand, Leqembi has become the first treatment shown to reduce the rate of disease progression and slow…

TKG Advisors LLC grew its position in Biogen Inc. (NASDAQ:BIIB - Free Report) by 8.5% during the 1st quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 10,896 shares of the biotechnology company's stock after purchasing an additional 849 shares during the period. Biogen comprises approximately 1.9% of TKG…

NeuroSense Therapeutics (NRSN) announced a deal with Biogen (BIIB) on Tuesday to run a biomarker study to evaluate its lead asset PrimeC in ALS. Read more here.

Biogen (BIIB) shares will remain on hold for trading as an FDA panel is set to discuss full approval for the Alzheimer's therapy Leqembi on Friday. Read more here.

Text size …